Bo‐Tao Xin

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Bešše, Lenka Bešše, Marianne Kraus et al. · Cell chemical biology · 2019 · 116 citations · Full text

Medicine, Molecular Biology, Oncology +16

Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes

Gerjan de Bruin, E.M. Huber, Bo‐Tao Xin et al. · Journal of Medicinal Chemistry · 2014 · 97 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +15

Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos

Raymond Kooij, Sijia Liu, Ayşegül Sapmaz et al. · Journal of the American Chemical Society · 2020 · 77 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents

Yu Jiao, Bo‐Tao Xin, Yanmin Zhang et al. · European Journal of Medicinal Chemistry · 2014 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +11

The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies

Salyan Bhattarai, Khetam Ghannam, Sabine Krause et al. · Journal of Autoimmunity · 2016 · 43 citations

Life Sciences, Immunology, Pathology +14